Explore HIMS stock analysis with the latest price trends, earnings beats, technical indicators, and balanced 2026-2027 forecast. Is HIMS stock a buy now? Get insights on valuation and outlook.
Introduction
HIMS stock tracks Hims & Hers Health, Inc., a telehealth leader offering personalized treatments for hair loss, sexual health, mental wellness, and weight management via app and website. Investors watch HIMS stock closely after strong 2025 results and 2026 guidance beating estimates. Broader market volatility from regulatory shifts in healthcare and tech weighs on sentiment, yet HIMS stock price shows resilience.
Latest Stock Price & Trend
As of last market close on March 13, 2026, HIMS stock price stands at $56.71, per recent data. It gained 10.3% in the prior session amid positive news flow. Over five days, HIMS stock rose 5%, reflecting momentum from earnings hype.
The one-month trend climbed 15%, driven by subscriber growth announcements. Three-month performance hit 25% up, while six months added 40% as weight-loss demand surged. Year-to-date in 2026, HIMS stock advanced 8%, despite early dips from guidance concerns.
The 52-week high reached $65.20, with a low of $22.50, placing current levels near the upper range. Overall trend stays bullish, signaling strong investor interest in HIMS stock forecast, though volatility persists. Investors see this as a sign of sustained demand in telehealth.
Technical Analysis
Support and Resistance
Support levels sit at $52 and $48, where buyers historically step in to prevent deeper drops. Resistance looms at $60 and $65, key hurdles for upward breaks. These levels guide entry and exit points for traders watching HIMS technical analysis.
RSI Reading
HIMS RSI analysis shows a reading of 62, neutral territory—not overbought above 70 or oversold below 30. RSI measures momentum; this suggests room for gains without immediate reversal risk.
MACD Trend
MACD signals bullish crossover, with the line above the signal, indicating building upward momentum. This oscillator spots trend shifts early, favoring buyers in HIMS stock.
Moving Averages
The 50-day moving average at $54.50 sits above the 200-day at $48.20, confirming uptrend strength. No golden cross recently, but the bullish alignment supports HIMS stock price stability. Moving averages smooth price action for trend spotting.
Trading Volume
Volume trends higher lately, averaging 8 million shares daily versus 6 million prior, showing conviction behind moves. Rising volume validates HIMS technical analysis for potential breakouts.
Analyst Ratings & Price Targets
Seventeen analysts rate HIMS stock: 11 Buy, 5 Hold, 1 Sell. Average price target hits $62, with highest at $75 and lowest $45. Recent Truist upgrade to Buy cites expansion potential.
Wall Street firms like Leerink see long-term value despite short-term regulatory noise. This mixed but leaning positive sentiment implies confidence in HIMS forecast, urging investors to weigh growth against risks.
Insider Activity
Insider activity shows net buying in Q1 2026, with CEO Andrew Dudum purchasing 50,000 shares at $50. No major selling reported recently. Trends point to management confidence in HIMS stock trajectory.
Small transactions from directors added 20,000 shares total. This buying pattern suggests insiders view HIMS valuation as attractive, signaling caution-free outlook for shareholders.
Valuation Analysis
Trailing P/E ratio stands at 29.26, forward P/E at 25. Price-to-sales is 4.2 based on $2.35B 2025 revenue. YoY revenue growth hit 59%, EPS growth surged 80% to support net income of $128M.
Free cash flow strengthened to $250M, with $500M cash and low debt (current ratio 1.9). Compared to peers like Teladoc (P/E 15, slower growth), HIMS appears fairly valued given superior revenue growth. HIMS stock leans fairly valued, not overpriced for its trajectory.
Recent Earnings & Catalysts
Q4 2025 revenue reached $617.8M, up 28% YoY but slightly below $619M expectations. EPS beat forecasts, with full-year 2025 at $2.35B revenue and $318M adjusted EBITDA. Forward guidance projects $2.7B-$2.9B for 2026, topping $2.74B consensus.
Catalysts include Eucalyptus acquisition for international push and new weight-loss offerings. Earnings dipped stock 5% initially on Q1 guide miss ($600M-$625M vs $654M expected), but long-term view stabilized HIMS stock.
Bullish Case
Revenue growth catalysts stem from 13% subscriber rise to 2.5M, targeting $6.5B by 2030. Market demand for affordable telehealth booms amid healthcare access gaps.
Technology edges like AI personalization and compounded GLP-1 drugs drive margins to 73.8%. Operational efficiencies from scale support sustained HIMS revenue growth.
Bearish Case
Competition intensifies from Ro and traditional pharma like Novo Nordisk. Regulatory risks around compounded drugs caused 52% YTD drops earlier.
Margin pressures from expansion and potential customer churn in weight loss loom. Economic slowdowns could hit discretionary spending on HIMS offerings.
Market Sentiment & Investor Psychology
Short interest hovers at 8% of float, moderate versus prior peaks. Options show call volume outpacing puts 2:1, bullish bias. Institutional ownership rose to 65%, steady accumulation.
Retail traders chase momentum on platforms, blending hype with value focus. Overall sentiment tilts optimistic on HIMS stock, tempered by regulatory fears.
Short-Term Outlook
Technical indicators like bullish MACD and rising volume point to upside tests of $60 resistance soon. Market momentum from guidance beats supports gains next weeks. Watch volume for confirmation on HIMS stock price moves.
Medium to Long-Term Outlook
Hims & Hers boasts a scalable telehealth model in a $100B+ market growing 15% annually. Competitive moat via subscriptions and data holds firm. Financial health shines with cash buffers.
Strategic edges like global expansion offset risks; long-term investors should accumulate on dips for HIMS long term outlook.
FAQ
Is HIMS stock a buy right now?
Yes for growth seekers, given beats and $62 average target, but monitor regulatory news.
What is the HIMS stock price target?
Analysts average $62, high $75; reflects 10-30% upside from $56.71.
What are major risks for HIMS stock?
Regulatory scrutiny on weight loss drugs and competition top concerns.
When are HIMS earnings next?
Q1 2026 results expected late April, with focus on subscriber adds.
What drives HIMS revenue growth?
Subscribers, new categories, and international via Eucalyptus deal.
Suggestion
Compare with Opendoor stock analysis.
See our Teladoc stock forecast.
Read our telehealth sector valuation breakdown.
Conclusion
Hold HIMS stock for patient investors eyeing telehealth expansion; watch for Q1 execution amid risks. Balanced growth justifies position, not aggressive buy yet.
Disclaimer: This article is for informational purposes only and not financial advice.